A large Australian study of the brain under psilocybin has found evidence of organisation within the neural changes that have...

Australia's modern psychedelic medicine story is usually traced to the Therapeutic Goods Administration's 2023 decision to allow authorised psychiatrists to...

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes...

The psychedelic medicine conference circuit is expanding as the field moves from clinical research towards treatment, regulation and healthcare delivery....

Emyria (ASX: EMD) has cleared a key operational bottleneck across its Perth and Queensland psychedelic-assisted therapy operations, with therapist availability...

A new executive order could position the US territory as a research destination for emerging psychedelic therapies as clinicians, researchers...

New Zealand is building a small but increasingly active psychedelic medicine sector, with clinical psilocybin access, Māori-led research and a...

For psychedelic investors, finding the next breakthrough company is the difficult part. Neo Kuma Ventures appears to have made at...

Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on...

Australia's psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to...